India’s CRISPR Sickle Cell Gene Therapy Workshop Highlights Colonial Biomedical Legacies & Tribal Sovereignty Gaps
Original framing: “Ministry of Tribal Affairs, CSIR and IGIB Organized Workshop on “BIRSA 101” — India’s First Indigenous CRISPR-Based Gene Therapy for Sickle Cell Disease” — bing news
Adivasi women’s groups in Chhattisgarh have protested CRISPR trials, arguing that gene editing distracts from demands for clean water and anemia-reducing diets in tribal schools. Dalit activists note that sickle cell is concentrated in marginalized castes, yet CRISPR’s 'indigenous' framing obscures caste-based discrimination in healthcare access. The workshop’s all-male, state-appointed panel excludes tribal healers, whose knowledge of plant-based remedies (e.g., *Tinospora cordifolia*) could complement or replace gene therapy.
The 'BIRSA 101' workshop exemplifies how neoliberal biomedical innovation co-opts indigenous symbolism to legitimize state power, obscuring the colonial legacies of sickle cell discourse in India.
While CRISPR offers a high-tech solution, its deployment risks repeating historical patterns of extractive research in tribal communities, where 90% of sickle cell cases persist due to structural inequities. Cross-cultural models—from Brazil’s Quilombola hybrids to Jamaica’s community circles—demonstrate that accessible, culturally grounded care outperforms gene therapy in marginalized populations. The workshop’s framing erases the voices of Adivasi women, Dalit activists, and tribal healers, whose resistance to CRISPR reflects a deeper demand for sovereignty over land, bodies, and knowledge. A systemic solution requires dismantling the biomedical-industrial complex’s monopoly on 'innovation' and centering tribal-led models that integrate genomics with ecological and spiritual healing, ensuring that 'indigenous' is not a marketing label but a lived practice of resistance and renewal.